SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., focuses on developing and commercializing treatments for disorders of the central nervous system, announced activities supporting the epilepsy community during Epilepsy Awareness Month in November
| FAIR LAWN, N.J., /PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., focuses on developing and commercializing treatments for disorders of the central nervous system, announced activities supporting the epilepsy community during Epilepsy Awareness Month in November. Through a series of grants and sponsorships, SK life science is raising awareness of epilepsy, helping families and caregivers whose lives are impacted by the disease, and working to enhance epilepsy treatment and care, nationally and locally.
“More than 3 million people in the U.S. live with epilepsy, an incredibly challenging condition that has significant effects on the physical and emotional health of patients and their families,” said Sebby Borriello, vice president and chief commercial officer at SK life science. “We are committed to listening to the unique needs of the epilepsy community and providing support for innovative programs that can help improve patients’ lives. We know progress requires a consistent, collective effort, and it is a privilege to recognize this dynamic community today and every day.” SK life science proudly supports the following initiatives: J. Kiffin Penry Epilepsy Education Programs: SK life science supports the world-renowned J. Kiffin Penry Epilepsy Education Programs, which provide comprehensive training for neurologists and epileptologists worldwide. SK life science has provided support for multiple education programs, including the Epilepsy MiniFellowship® and the Residents Epilepsy Program, which facilitate lectures, discussions and workshops featuring leading clinicians and researchers, so young neurologists and fellows have access to knowledge and tools that will help them provide the best care for their patients. National Caregivers Conference: SK life science supported the National Caregivers Conference hosted by the Family Resource Network, held on October 11, 2018 in Iselin, New Jersey. The National Caregiver Conference showcased exciting projects that use technology to improve the health and quality of life of caregivers and their loved ones. The impact of epilepsy often transcends the individual living with the disease and often requires substantial support from friends and families. Annual Glow Walk Run: SK life science will support the 5th Annual Glow Walk Run benefiting Epilepsy Services of New Jersey (ESNJ), an organization that helps raise awareness and funds to provide education, recreation and support to individuals living with epilepsy in New Jersey. The event will take place on November 10, 2018 at Liberty State Park in Jersey City, New Jersey. About SK life science SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., is focused on developing and commercializing treatments for disorders of the central nervous system (CNS). Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is located in Fair Lawn, New Jersey. We have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound in a Phase 3 global clinical trial for the potential treatment of epilepsy in adult patients. For more information, visit SK life science’s website at www.SKLifeScienceInc.com. About SK biopharmaceuticals For more information, visit SK biopharmaceuticals’ website at www.skbp.com. Media Contact:
SOURCE SK Life Science, Inc. |
View original content to download multimedia:
